

**Clirinx Limited**

**Abridged Financial Statements  
for the year ended 30 June 2025**

## Clirinx Limited

### Contents

	<b>Page</b>
Company Information	3
Accountants' Report	4
Abridged Balance Sheet	5
Notes to the Financial Statements	6

## **Clirinx Limited**

### **Company Information**

<b>Principal activity</b>	The principal activity of the company is the development of software for medical researchers.
<b>Directors</b>	Gerard Nesbitt Patricia Murphy
<b>Secretary</b>	Patricia Murphy
<b>Company number</b>	515782
<b>Registered office and business address</b>	Tobergregan Garristown Co. Dublin A42 YK18
<b>Accountants</b>	Chapman & Associates Chartered Certified Accountants and Tax Consultants Chester Lodge Curragha Road Ratoath Co. Meath
<b>Bankers</b>	Allied Irish Banks p.l.c. Howth Road Dublin 5
<b>Solicitors</b>	Gaffney Halligan 413 Howth Road Dublin 5

## **Accountants' Report to the directors on the unaudited financial statements of Clirinx Limited**


In order to assist the directors to fulfil their duties under the Companies Acts, we have prepared for their approval the financial statements of Clirinx Limited for the year ended 30 June 2025 from the company's accounting records and from information and explanations they have given to us.

As a practising member firm of the Association of Chartered Certified Accountants (A.C.C.A.), we are subject to its ethical and other professional requirements which are detailed at [www.accaglobal.com/rulebook](http://www.accaglobal.com/rulebook).

This report is made solely to the Board of Directors of Clirinx Limited, in accordance with the terms of our engagement. Our work has been undertaken solely to prepare for the director's approval the financial statements of Clirinx Limited and state those matters that we have agreed to state in this report in accordance with guidance from the A.C.C.A. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Clirinx Limited and its Board of Directors for our work or for this report.

It is the director's duty to ensure that Clirinx Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit or loss. The directors have approved the Profit and Loss Account, Balance Sheet and related notes for the year ended 30 June 2025 and have acknowledged their responsibility for them, for the appropriateness of the financial reporting framework adopted and for providing all information and explanations necessary for their completion. The directors consider that Clirinx Limited is exempt from the statutory audit requirement for the year ended 30 June 2025.

We have not been instructed to carry out an audit or a review of the financial statements of Clirinx Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations given to us and we do not, therefore, express any opinion on the statutory financial statements.



**Kenneth Chapman F.C.C.A.**

**For and on behalf of Chapman & Associates  
Chartered Certified Accountants  
& Tax Consultants**

**Chester Lodge  
Curragha Road  
Ratoath  
Co. Meath**

**Date: 29 January 2026**

**Clirinx Limited**  
**Abridged Balance Sheet**  
**as at 30 June 2025**


	<b>2025</b>	<b>2024</b>
	€	€
<b>Fixed assets</b>	<b>2,872</b>	3,353
<b>Current assets</b>	<b>31,918</b>	36,668
<b>Creditors: amounts falling due within one year</b>	<b>(15,376)</b>	(2,967)
<b>Net current assets</b>	<b>16,542</b>	33,701
<b>Total assets less current liabilities</b>	<b>19,414</b>	37,054
<b>Accruals and deferred income</b>	<b>(3,280)</b>	(2,980)
<b>Net assets</b>	<b>16,134</b>	34,074
<b>Capital and reserves</b>	<b>16,134</b>	34,074

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the micro-entity regime and in accordance with Financial Reporting Standard 105 'The Financial Statement Reporting Standard applicable to the Micro-entities Regime'.

We the directors of Clirinx Limited state that;

- (a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014
- (b) the company is availing itself of the exemption on the grounds that the conditions specified in Section 358 are satisfied
- (c) the shareholders of the company have not served a notice on the company under Section 334(1) in accordance with Section 334(2) of the Companies Act 2014
- (d) We acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare Financial Statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a year and to otherwise comply with the provisions of the Companies Act 2014 relating to Financial Statements so far as they are applicable to the company.
- (e) The company has relied on the specified exemption contained in Section 352; We have done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged Financial Statements have been properly prepared in accordance with Section 353 of the Companies Act 2014.

On behalf of the board



**Gerard Nesbitt**  
**Director**



**Patricia Murphy**  
**Director**

**Date: 29 January 2026**

**Date: 29 January 2026**

## Clirinx Limited

### Notes to the Financial Statements for the year ended 30 June 2025

#### General information and accounting policies

The financial statements have been prepared in accordance with the micro-entity provisions and under the historical cost convention. The financial statements are presented in euro, which is the company's functional and presentation currency and is denoted by the symbol "€". The significant accounting policies adopted are set out below.

#### Tangible fixed assets and depreciation

Tangible fixed assets are stated at cost less accumulated depreciation. Depreciation charge is calculated to write down cost to their estimated residual values by equal annual instalments over their expected useful lives, which are as follows:

Class of asset	Basis of depreciation	Estimated useful life
Fixtures, fittings & equipment	15% Straight Line	7 years

#### Transactions in foreign currencies

Transactions in foreign currencies are recorded at the rate ruling at the date of the transactions or at a contracted rate. The resulting monetary assets and liabilities are translated at the balance sheet rate or the contracted rate and the exchange differences are dealt with in the profit and loss account.

#### Turnover

Turnover represents the invoice value of services supplied by the company, exclusive of trade discounts and V.A.T.

#### Employee benefits

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund.

#### Directors loans, credit and guarantees

At the end of the financial year, Gerard Nesbitt, a director of the company, was owed €11,277 from the company. The loan is interest free and is payable on demand.

Movement on profit and loss reserves	2025 €	2024 €
Profit and loss reserves at start of the year	33,974	25,839
(Loss)/profit for the year	(17,940)	8,135
Profit and loss reserves at end of the year	<u>16,034</u>	<u>33,974</u>
<b>Share capital</b>	<b>2025 €</b>	<b>2024 €</b>
<b>Allotted, called up and fully paid equity</b>		
100 Ordinary shares of €1 each	<u>100</u>	<u>100</u>


#### Directors and their interests


The directors who served during the year and their respective shareholding were as stated below:

	Number of Ordinary Shares as at 30 June 2025	Number of Ordinary Shares as at 30 June 2024
Gerard Nesbitt	50	50
Patricia Murphy	50	50

#### Approval of financial statements

These financial statements were approved by the board of directors and signed on behalf of the board

  
 Gerard Nesbitt  
 Director

  
 Patricia Murphy  
 Director

The financial statements were approved by the directors on 29 January 2026